PM360 July 13, 2023 Read the full article>> Reasons for Discontinuation (RfD) Analytics Report An estimated 50% of patients with a prescription for a chronic condition stop taking it within the first year, leading to worse outcomes and nearly $250 billion lost revenue annually for the pharmaceutical industry. To combat this, OM1 launched its Reasons for Discontinuation[…]
Patti Peeples June 22, 2023 The Evidence Base Watch the full interview >>
Register to watch>> Join a panel of OM1’s clinical experts in cardiometabolic disease, immunology, and mental health as they explore how Artificial Intelligence (AI) can find phenotypic patterns and unlock insights hidden in real-world data. Extracting as much information as possible from real-world datasets is essential for understanding the complete patient journey. Subtle patterns in[…]
PM360 MAY 25, 2023 Andrew Matthius Read the full article>> Mental health continues to be a national crisis that is only becoming more prevalent, especially since the pandemic. According to the National Alliance on Mental Illness (NAMI), 22.8% of U.S. adults experienced mental illness in 2021, which represents about 1 in 5 adults or 57.8 million[…]
Business Wire May 24, 2023 Read the full press release>> OM1 now offers a complementary suite of easy-to-digest analytics that give a real-world, 360° view of trends in treatment behaviors and patient outcomes May 24, 2023 09:00 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–OM1, a leading real-world data, outcomes, and technology company with a focus on chronic[…]
